INTRODUCTION

Choroidal metastasis occurs in 7–11% of patients with breast carcinomas (1). Treatment includes external beam radiation therapy, tamoxifen, aromatase inhibitors (letrozole) and chemotherapy, including systemic bevacizumab (1–3). Bevacizumab, a monoclonal antibody is anti-angiogenetic, thereby limiting tumour vascularization and growth. It has been approved for systemic use in colon carcinomas (4).  Its “off label” use in ophthalmology has evolved from the treatment of age-related macular degeneration (ARMD) to proliferative diabetic retinopathy (PDR) and macula oedema (5–8). Bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, reduces permeability and allows resorption of subretinal fluid. It also prevents angiogenesis, a mechanism that inhibits further tumour growth.